Shanghai Henlius Biotech Inc (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company, which includes research, development, production and marketing of monoclonal antibody products. It develops medicine for oncology, autoimmune and ophthalmic diseases. The company offers products such as rituximab injection for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma; trastuzumab for breast cancer, metastatic gastric cancer and metastatic breast cancer; and adalimumab injection for ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis and uveitis. It also offers bevacizumab injection and serplulimab injection. The company operates research and development centers in Shanghai, China and the US. Henlius is headquartered in Shanghai, China.
Headquarters
China
Address
9Floor, Innov Tower (Capitaland Building), 1801 Hongmei Road, Shanghai, 200233
Website
www.henlius.com
Telephone
86 21 33395800
No of Employees
3,637
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2696 (HKG)
Revenue (2022)
$762.8M
67.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
178.5%
(2022 vs 2021)
Market Cap*
$1.0B
Net Profit Margin (2022)
XYZ
146.8%
(2022 vs 2021)
* As of and is in US$
Shanghai Henlius Biotech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rituximab Injection | Henlius |
| Adalimumab Injection | |
| Bevacizumab Injection | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In March, the company's HANQUYOU was approved for marketing in Thailand and the Philippines under the trade names TRAZHER and Hertumab respectively to treat patients with HER2-positive breast cancer and gastric cancer. |
| 2023 | Regulatory Approval | In November, the company's HLX42 for Injection, the ADC product received approval from the U.S. Food and Drug Administration for the treatment of advance/metastatic solid tumors. |
| 2023 | Contracts/Agreements | In October, Hengenix Biotech entered into a collaboration with OncoHost to offer high-quality, affordable, and innovative biologic medicines for patients worldwide. |
Competitor Comparison
| Key Parameters | Shanghai Henlius Biotech Inc | Jinyao Pharmaceutical Co Ltd | Sihuan Pharmaceutical Holdings Group Ltd | BrightGene Bio-Medical Technology Co Ltd | Ascletis Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Tianjin | Beijing | Suzhou | Hangzhou |
| State/Province | Shanghai | Tianjin | Beijing | Jiangsu | Zhejiang |
| No. of Employees | 3,637 | 2,678 | 3,241 | 1,128 | 219 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wenjie Zhangi | Chief Executive Officer; Chairman | Executive Board | 2021 | 56 |
| Jun Zhu | Chief Financial Officer; President | Senior Management | 2023 | 44 |
| Huang Wei | Senior Vice President; Chief Operating Officer | Senior Management | - | - |
| Zhang Jifeng | Senior Vice President; Chief Technology Officer | Senior Management | - | - |
| Cao Ping | Chief Business Development Officer; Vice President - Business Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward